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Abstract
Purpose—Several genes encoding complement system components and fragments are associated
with age-related macular degeneration (AMD). This study was conducted to determine whether
alterations in circulating levels of these markers of complement activation and regulation are also
independently associated with advanced AMD and whether they are related to AMD genotypes.
Methods—Plasma and DNA samples were selected from individuals in our AMD registry who had
progressed to or developed the advanced stages of AMD, including 58 with geographic atrophy and
62 with neovascular disease. Subjects of similar age and sex, but without AMD, and who did not
progress were included as controls (n = 60). Plasma complment components (C3, CFB, CFI, CFH,
and factor D) and activation fragments (Bb, C3a, C5a, iC3b, and SC5b-9) were analyzed. DNA
samples were genotyped for seven single-nucleotide polymorphisms in six genes previously shown
to be associated with AMD: CFB, CFH, C2, C3, and CFI and the LOC387715/ARMS2 gene region.
The association between AMD and each complement biomarker was assessed by using logistic
regression, controlling for age, sex, and proinflammatory risk factors: smoking and body mass index
(BMI). Functional genomic analyses were performed to assess the relationship between the
complement markers and genotypes. Concordance, or C, statistics were calculated to assess the effect
of complement components and activation fragments in an AMD gene-environment prediction
model.
Results—The highest quartiles of Bb and C5a were significantly associated with advanced AMD,
when compared with the lowest quartiles. In multivariate models without genetic variants, the odds
ratio (OR) for Bb was 3.3 (95% confidence interval [CI] = 1.3-8.6), and the OR for C5a was 3.6
Copyright © Association for Research in Vision and Ophthalmology
Corresponding author: Johanna M. Seddon, Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center, 800 Washington
Street, Box 450, Boston, MA 02111; jseddon@tuftsmedicalcenter.org..
Disclosure: R. Reynolds, None; M.E. Hartnett, None; J.P. Atkinson, None; P.C. Giclas, None; B. Rosner, None; J.M. Seddon, P
NIH Public Access
Author Manuscript
Invest Ophthalmol Vis Sci. Author manuscript; available in PMC 2010 February 23.
Published in final edited form as:













(95% CI = 1.2-10.3). With adjustment for genetic variants, these ORs were substantially higher. The
alternative pathway regulator CFH was inversely associated with AMD in the model without
genotypes (OR = 0.3; P = 0.01). Positive associations were found between BMI and plasma C3, CFB,
CFH, iC3b, and C3a. There were also significant associations between C5a fragment and
LOC387715/ARMS2 and C3 genotypes (P for trend = 0.02, 0.04), respectively. C statistics for models
with behavioral and genetic factors increased to 0.94 ± 0.20 with the addition of C3a, Bb, and C5a.
Conclusions—Increased levels of activation fragments Bb and C5a are independently associated
with AMD. Higher BMI is related to increased levels of complement components. C5a is associated
with AMD genotypes. C statistics are stronger with the addition of C3a, Bb, and C5a in predictive
models. Results implicate ongoing activation of the alternative complement pathway in AMD
pathogenesis.
Several genes in the complement pathway are known to be associated with age-related macular
degeneration (AMD), including CFH, CFB, C2, C3, and CFI.1-9 These associations point to
the involvement of inflammatory and immune mechanisms, especially the complement system,
in the development of AMD. Another gene in the LOC387715/ARMS2 region on chromosome
10 is related to AMD, although the mechanism is uncertain.10-13 Behavioral and modifiable
factors, such as smoking and body mass index (BMI), which are related to AMD,14 influence
levels of inflammatory biomarkers,15,16 and also modify genetic susceptibility.17 We tested
levels of complement components (C3, CFB, CFI, CFH, and factor D) and activation fragments
(Bb, C3a, C5a, iC3b, and SC5b-9) in plasma samples from cases with advanced AMD and
controls, to further assess the role of the complement system and its association with AMD.
In addition, we determined the association of these biomarkers with behavioral factors related
to AMD and their association with AMD genotypes. Finally, we assessed the degree to which
these components and activation fragments contribute to the algorithm previously shown to
predict the prevalence and incidence of advanced AMD.18
Methods
Study Population
Patients with and without AMD were enrolled in our genetic epidemiologic studies, using
standardized clinical examinations, questionnaires, and fundus photography, as previously
described.19-21 Grades were based on clinical and fundus photographic data using the Clinical
Age-Related Maculopathy Grading System (CARMS).22 From our AMD registry, we selected
180 unrelated Caucasian individuals with DNA and plasma samples. The 120 patients (60 men
and 60 women), included 58 individuals with geographic atrophy (GA) and 62 with neovascular
disease (NV). Among the patients, 108 had a baseline CARMS grade of 1, 2, or 3 and
progressed to either grade 4 with central or noncentral GA (n = 48) or grade 5 with NV (n =
62) in one or both eyes. Controls (n = 60) had a CARMS grade of 1 in both eyes, did not
progress, and consisted of 30 men and 30 women. The mean ± SD of ages of the case and
control groups was 82 ± 6.9 and 79 ± 4.4 years, respectively. The research complied with the
tenets of the Declaration of Helsinki and was approved by the institutional review board.
Informed consent was obtained from all subjects.
Genotyping
DNA samples were genotyped for seven single-nucleotide polymorphisms (SNPs) in genes
previously demonstrated to be related to AMD: (1) complement factor H CFHY402H
rs1061170 in exon 9 of the CFH gene on chromosome 1, region q32, a change 1277T>C,
resulting in a substitution of histidine for tyrosine at codon 402 of the CFH protein; (2) CFH
rs1410996, an independently associated SNP variant within intron 14 of CFH; (3)
LOC387715/A69S ARMS2 (rs10490924 in the LOC387715/ARMS2 region of chromosome
10, a nonsynonymous coding SNP variant in exon 1 of LOC387715), resulting in a substitution
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of the amino acid serine for alanine at codon 69; (4) complement component 2 or C2BE318D
(rs9332739), the nonsynonymous coding SNP variant in exon 7 of C2 resulting in a substitution
of aspartic acid for glutamic acid at codon 318; (5) complement factor B or CFBR32Q
(rs641153), the nonsynonymous coding SNP variant in exon 2 of CFB resulting in the
substitution of the amino acid glutamine for arginine at codon 32; (6) complement component
3 or C3R102G (rs2230199), the nonsynonymous coding SNP variant in exon 3 of C3 resulting
in the substitution of the amino acid glycine for arginine at codon 102; and (7) complement
factor I CFIrs10033900, an independently associated SNP located in the linkage peak region
of chromosome 4, 2781 bp upstream of the 3′ untranslated region of CFI.
For the genetic variant on chromosome 10, LOC387715A69S, it remains a subject of debate
whether the gene HTRA1 adjacent to it may in fact be the AMD susceptibility gene on
10q2610-13; however, the relevant SNPs in these two genes have been reported to be in near-
perfect correlation. Thus, although the other SNP is a promising candidate variant, rs10490924,
used in this study, can be considered a surrogate for the causal variant that resides in this region.
For the C2/CFB genes, there are two independent associations to the C2/CFB locus, but because
of linkage disequilibrium, we do not know whether one of the two genes or both are functionally
affected.1,2 Genotyping was performed using primer mass extension and MALDI-TOF MS
analysis (MassEXTEND methodology; Sequenom, San Diego, CA) at the Broad Institute
Center for Genotyping and Analysis (Cambridge, MA).
Plasma Samples and Complement Components and Activation Fragments
Fasting plasma samples were drawn into tubes (BD Biosciences, Bedford, MA) containing
K2 EDTA, primarily at time-of-baseline grade. The blood was centrifuged and plasma
separated within 30 minutes of collection. The samples were frozen and stored in liquid
nitrogen until testing was performed. The following complement activation fragments and
complement system proteins were analyzed in the Complement Laboratory of PCG: Bb, C3a,
C5a, iC3b, SC5b-9, C3, factor D, CFB, CFH, and CFI.
C3 was measured by standard clinical laboratory nephelometric methods. CFB, CFH, and CFI
were measured by radial immunodiffusion (RID) with anti-human antibodies specific for the
individual proteins in 1% agarose gels.23 The CFH antiserum (Quidel, San Diego, CA) was
produced against purified human factor H. It is specific for CFH but has not been evaluated
for cross-reactivity to the CFH-related proteins. The complement laboratory reference range
for CFH is 160 to 412 μg/mL, in agreement with ranges used by other complement reference
laboratories in the United States and Europe. The antibodies used for CFB and CFI are also
goat polyclonal antisera specific for the given proteins (Quidel). Purified CFB, CFH, and CFI
were used to standardize the assays (Quidel, and CompTech, Tyler TX). Appropriate controls
were included with each batch of patient samples, and the results were calculated from the area
under the precipitin rings.
Factor D was measured by ELISA (Quantikine kit; R&D Systems, Minneapolis, MN), with a
plate precoated with specific monoclonal antibody for factor D. The standard provided with
the kit is 40 ng of recombinant human complement factor D (CFD). The enzyme conjugate is
polyclonal anti-CFD linked to horseradish peroxidase. Three controls: high, medium, and low,
are run with each set of samples. The reference range given by the manufacturer is 1468 to
3657 ng/mL for EDTA plasma. The reference range established by the complement laboratory
is 1688 to 3076 ng/mL for EDTA plasma, which was converted to μg/mL: 1.69 to 3.08 (mean
± 2 SD) for reporting in this study.
Complement activation markers were measured by commercially available ELISA kits with
extra in-house controls. Bb, iC3b, and SC5b-9 ELISA kits were from Quidel. The tests for C3a
and C5a were performed with kits (OptEIA) from BD-Pharmingen (San Diego, CA). Reference
Reynolds et al. Page 3













ranges for all the complement fragments were established in the complement laboratory under
stringent validation protocols. Reference ranges for the assays are as follows: C3a (305-1239
ng/mL), C5a (5.0-25.4 ng/mL), Bb (0.41-1.49 μg/mL), iC3b (0-17.4 ng/mL), and SC5b-9
(72-244 ng/mL). The complement laboratory is accredited by the College of American
Pathologists and the Clinical Laboratory of 1988 to perform tests of high complexity.
Covariates
Data on smoking were collected from a standardized risk factor questionnaire. Smokers were
defined as having smoked at least one cigarette per day for 6 months or longer. Pack years
were calculated by multiplying the number of cigarettes smoked per day by the number of
years smoked divided by 20. Height and weight were measured at the time of the baseline grade
to calculate BMI (weight in pounds, multiplied by 703, divided by height in inches squared),
or in a few instances by self-report.
Statistical Analysis
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for covariates, and
genotypes by using logistic regression (controlling for age [60-79, 80+] and sex) to evaluate
their association with each maculopathy group (GA and NV), and total AMD (GA and NV
combined), with controls. t-Tests were used to calculate probabilities values for age between
cases and controls. P ≤ 0.05 was considered statistically significant for all analyses.
The Wilcoxon rank sum test was used to calculate probabilities to assess the relationship
between the median plasma level of complement components and activation fragments and
maculopathy group.
ORs and 95% CIs for total AMD were computed to compare the fourth quartile with the first
quartile of the component and activation fragments using logistic regression. In model A, we
controlled for age (60-79, 80+), sex, BMI (<25, 25-29.9, 30+), and smoking (ever, never). In
model B, we controlled for the same factors as in model A, plus all the genotypes: CFB (CC
and CT/TT), CFH:Y402H (TT, CT, and CC), CFH:rs1410996 (TT, CT, and CC), C2 (GG and
CG/CC), LOC387715/ARMS2 (GG and GT/TT), C3 (CC, CG, and GG), and CFI (CC, CT,
and TT).
ORs and 95% CIs for AMD were calculated for each genotype separately with one component
or activation fragment at a time to assess whether the effect of genotype was mediated by that
complement component or activation fragment. We used log component and activation
fragment values, because the distribution was slightly skewed, to assess associations with
genotype among controls using linear regression. In addition, linear regression was used to test
the relationship between each complement component or activation fragment and smoking and
BMI, both among the controls and among the cases and controls combined. To see whether
the effects of genotype and complement components and activation fragments were dependent
on one another, we used logistic regression to test for interaction effects on risk of AMD.
General linear model analysis was used to calculate the least-squares (LS) mean, to assess the
relationship between the mean level of components or fragments and genotype among the cases
and controls combined. In this model we controlled for age, sex, AMD status, and all the
genotypes.
Concordance, or C, statistics were calculated to assess whether activation fragments contribute
to the predictability of developing advanced AMD. Similar to our previous studies,16,18,24
the area under the receiver operating characteristic (ROC) curve was obtained, and an age-
adjusted C statistic based on the ROC curve was calculated. C statistics were calculated for six
models with various combinations of covariates, genotypes, and activation fragments, to assess
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the probability that the risk score from a random case was higher than the corresponding risk
score from a random control, based on the group of risk factors in each model, such that a
perfect score would be 1.0, or 100%, predictability. We obtained standard errors of estimated
C statistics and compared C statistics from alternative risk prediction models by using
correlated ROC curve methods.
Results
Table 1 shows associations between increasing age and all AMD groups. The NV-only and
total AMD groups were more likely to be smokers or heavy smokers and had higher BMIs than
did the control subjects, although these associations were not statistically significant. All
genotypes were associated with both types of advanced AMD. There was a significant
protective effect of genotype CFB (CT/TT) for GA and a trend for reduced risk of NV, compared
with CC genotype. There were strong positive associations between the CFH Y402H and
CFH: rs1410996 CC genotypes (vs. TT) and both forms of advanced AMD, and a protective
association of C2 CG/CC (vs. GG) with overall AMD and GA. LOC387715/ARMS2 GT/TT
was associated with AMD compared with GG. The C3 GG genotype was positively associated
with GA, and a similar trend was seen for NV. For CFI, ORs were in the direction of increased
risk for the T allele for both GA and NV (P-trend = 0.08 for total AMD).
Table 2 shows that the median levels of the activation fragments, Bb, C3a, and C5a, were
significantly higher in the GA group than in the control group. CFH component was
significantly lower in the GA group than in the control group (median of 289 vs. 312 μg/mL,
P = 0.008). Results for the total AMD group were similar to those for the GA group.
Table 3 shows a positive association between activation fragment Bb and the total AMD group,
both with and without adjustment for genotype (OR = 3.3, 95% CI = 1.3-8.6, and OR = 5.4,
95% CI = 1.3-22.9, respectively). Similar results were found for C5a (OR = 3.6, 95% CI =
1.2-10.3; OR = 25.2, 95% CI = 3.7-171.7), with and without adjustment for genotypes,
respectively. CFH component had a significant inverse association with AMD in the model
that did not control for genotype (OR = 0.3, 95% CI = 0.09-0.75, P = 0.01), and which became
nonsignificant after adjustment for genotype.
Table 4 shows the change in the association between genotype and AMD, with addition of
complement fragments Bb, C5a, and component CFH to the models. The ORs for risk of AMD
increased for both CFH loci, LOC, and CFI genotypes, with the addition of activation fragment
C5a into the statistical models. There was also an increase in the OR for the C3 gene when the
CFH component was added to the model. The associations of the other genetic loci with AMD
(data not shown) were not materially changed after inclusion of complement components and
activation fragments one at a time.
We found significant associations between BMI ≥ 25 and increased levels of fragments C3a
and iC3b, and component CFH among the control subjects (Table 5). When the entire study
population was included to further assess these relationships, controlling for AMD status, CFH
remained significant, CFB and C3 became significant (P = 0.001 and 0.005, respectively), and
C3a and iC3b became nonsignificant. We found no significant association between
complement components or fragments and smoking.
Interactions between genotypes and components and fragments were also assessed (data not
shown). We found a significant interaction between component CFH and the protective CFB
genotype (P interaction = 0.04). This finding indicates that the component CFH is inversely
associated with risk of AMD among individuals with the CFB genotype CC, but is unrelated
to risk of AMD in the presence of a protective allele CFB genotype of CT/TT.
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When controlling for all genotypes, we found significant associations between the LS mean
for fragment C5a and the LOC387715/ARMS2 and C3 genotypes, although the differences
were small (Table 6). For the LOC387715/ARMS2 genotype, the LS mean for C5a was lower
with the addition of the risk allele T. For the C3 genotype the trend for increasing C5a is
significant with the addition of each risk allele. The Bb LS means are negative because they
are on a log scale and have values less than 1 in some instances.
C statistics for all cases versus controls were calculated for various models to assess the
predictability of advanced AMD (Table 7): model 1 (age, sex, AMD status, smoking, and BMI);
model 2 (all variables in model 1 plus genetic variants CFB, CFH:Y402H, CFH:rs1410996,
C2, LOC387715/ARMS2, C3, and CFI); and models 3, 4, 5, and 6 (model 2 plus fragments
C3a, Bb, and C5a, and all three markers, respectively). There were significant increases in C
statistics on adding Bb (0.870) and C5a (0.895) in model 2 (P = 0.029, 0.043, respectively).
Combining C3a, Bb, and C5a in the model resulted in a C statistic of 0.944 and a P < 0.001
compared with model 2. We plotted the frequency distribution of risk scores separately for
cases and controls for model 6, selecting a cutoff of 4 (risk score ≥ 0), which yields a sensitivity
of 88% and a specificity of 73% (Fig. 1). In general, cases had higher risk scores than the
controls.
Discussion
In our analyses, we found an independent relationship between activation fragments Bb and
C5a and advanced AMD. Our study provides new information regarding the association
between the complement system and AMD in several ways. We evaluated each complement
component or fragment, both with and without seven AMD genotypes, controlling for other
covariates including age, sex, smoking, and BMI. We found a significant association between
median levels of fragments Bb and C5a and advanced AMD as well as the GA group separately.
There was a significant inverse association between the median level of CFH component and
the total AMD group and the GA group separately. Median C3a level was significantly higher
among GA cases, but this association was not significant after adjustment for other genetic and
nongenetic factors. Some associations were stronger in GA cases than NV cases, compared
with controls. Reasons for this are unclear, and additional studies may clarify the biologic
mechanisms responsible for these differences in advanced AMD.
Bb is a catalytic domain of the alternative pathway C3 convertase, C3bBb. Upon decay or
disassociation of this two-part protein complex by complement regulators such as the
membrane protein decay accelerating factor (DAF, CD55) or the plasma protein factor H, Bb
is liberated into the surrounding milieu. Thus, it is a marker of alternative pathway activation
and increased levels provide strong evidence for engagement of the alternative pathway in
AMD patients. Of note, elevated levels of Bb were also recently reported in preeclampsia,
another condition in which excessive alternative pathway activation has been implicated in
etiopathogenesis.25 Preeclampsia is characterized by small vessel angiopathy and rare
mutations in the complement regulatory proteins of the alternative pathway have also been
identified in this condition and in the hemolytic uremic syndromes, another
thrombomicroangiopathy.25,26
We also found associations between higher BMI and activation fragments C3a, iC3b, and
component CFH among the control subjects, as well as associations between BMI and
components C3, CFB, and CFH among the entire study population, when controlling for AMD.
Higher BMI is a known risk factor for the development of AMD,14,17,24 it has been shown to
be related to higher CRP,15,16 and the independent association between BMI and complement
components and fragments found in this study is also noteworthy. We found a significant
inverse association between C5a fragment and LOC387715/ARMS2 genotypes, and significant
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positive trend between C3 genotypes and higher C5a fragment. We calculated ROC curves and
C statistics for C3a, Bb, and C5a which included demographic and environmental covariates
and seven SNPs. Significant increases in C statistics were observed when these fragments were
added to the prediction model, especially when they were considered together, with
discrimination between advanced AMD and a control increasing to as high as 94%. These
findings add to the evidence that the complement system, in particular the alternative pathway,
is activated and involved in the development of advanced AMD, such as through chronic low-
level activation of complement in the retina.
In AMD, there is increased complement deposition in Bruch’s membrane and in drusen.27
Photo-oxidation of bisretinoid lipofuscin in cultured RPE cells has been shown to lead to
complement activation and release of fragments iC3b and C3a in vitro.28 This finding supports
the thinking that increased complement activation in AMD may occur as a result of photo-
oxidation within RPE. Having insufficient functional CFH to dampen the complement-induced
injury in the outer retina may then lead to pathologic features in advanced AMD. This line of
thinking also is supported by the inverse relationship we found between CFH and AMD for
analyses that were not controlled by genotype. The major predisposing effect is thus one of
decreased regulation of activation of the complement cascade in the retina, such as through
dysfunctional CFH gene protein or from insufficient production of protein. Whether there is
systemic activation of the complement system or the elevated levels reflect systemically
circulating fragments from local activation in the eye (as is observed in rheumatoid arthritis
with complement activation in a joint) is not clear.29 These are not mutually exclusive
possibilities, in that both systemic activation and local (i.e., retinal) complement activation
could play a role. The latter is established based on findings of complement deposition in
drusen.27 Biologically, the same outcome would occur if CFH were present in lower than
normal amounts or were not fully functional. Complement activation, although probably not
the initiating cause of the injury in AMD, can nevertheless substantially contribute to
subsequent tissue damage. Animal models of laser induced damage to Bruch’s membrane
provide evidence of the importance of C5a and other components of alternative pathway in the
development of choroidal neovascularization.30,31 Elevated plasma activation fragments Bb,
C3a, and C5a are consistent with continuous, low-level alternative pathway activation in
patients with advanced AMD. In sum, we hypothesize that subtle alterations in the efficiency
of activation and/or in regulatory capacity negatively influence a pathologic process that plays
out over the years.
Activation of the complement system may lead to the formation the membrane attack complex
(MAC or C5b-9). This terminal pathway begins with the cleavage of C5 to C5a and C5b.
SC5b-9 is the fluid phase terminal complex that usually circulates bound to the inhibitor
vitronectin. The quantity of SC5b-9 in the circulation is in part a reflection of the MAC that is
generated locally. Thus, a fraction is deposited at the site and part is in the fluid phase. Our
results and those of others indicate increased activation of C5 based on the elevated C5a levels
in the blood and deposition of C5b-9 in the retina in AMD patients. C5a can bind to its receptor,
C5aR, and has been shown to be important in models of AMD.32 C5b can be generated by
activation of the alternative pathway or by direct cleavage by proteases including trypsin and
thrombin. A recent report provided considerable evidence to indicate C5 activation by thrombin
in a lung model of immune complex activation.33 In our study, the SC5b-9 was not increased
in AMD, although it was in a similar study by Scholl et al.34 That study had few GA patients,
and we speculate that the efficiency of C5b-9 deposition and retention in the two forms or the
difference in the proportion of the types of advanced disease compared with our sample may
account for the differences in results regarding MAC and other differences between the two
reports. Another possibility relates to the quantity of local versus systemic activation which
could alter the ratio of blood to tissue MAC. We still have much to learn about how the
complement system is triggered and regulated, especially in niche locations such as the retina.
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BMI is a known risk factor for the development of AMD.14,17,24 The association described
in this report between high BMI and elevated C3, CFB, and CFH as well as increased
concentrations of complement activation fragments derived from several components of the
alternative pathway point to a role of the complement system in obesity. Adipose tissue is the
source of acylation-stimulating protein (ASP), which is also C3a desArg. C3a desArg is a C3-
derived protein formed by removal of an arginine from the carboxyl terminus of C3a and is
the major form of circulating C3a. Before the relationship to C3 was discovered, the lipogenic
function of ASP/C3a desArg was discovered.35 Sivaprasad et al.36 studied C3a desArg as an
indicator of C3 systemic complement activation among 84 cases of advanced AMD (42 GA,
42 NV), as well as in association with the CFH:rs1061170 genotype. They found no significant
association between genotype and C3a desArg, but did find an increase in C3a desArg
concentration among cases, which suggests systemic activation. Largely consistent with these
data, we found associations with C3a and AMD, and additionally found a new association
between a second C3 split product, iC3b and BMI. Adipsin, an adipose-specific factor linked
to adipocyte differentiation, was shown to be factor D of the alternative pathway of the
complement system.37 We did not find a relationship with plasma factor D, whereas a previous
study showed factor D was increased among patients with AMD compared with controls with
a different proportion of geographic atrophy to neovascular AMD cases.34 Other noteworthy
adipose-complement alterations include altered lipid clearance in C3−/− mice and partial
lipodystrophy in children with an autoantibody that stabilizes the alternative pathway C3
convertase.38,39 Also, there are a few reports of elevated C3 concentrations in individuals with
a high BMI.40,41 Our data support increased turnover and activation of the alternative pathway
in individuals with high BMI, evidenced by increased activation fragments, Bb, C3a, and iC3b.
Enhanced alternative pathway activation in obesity and in AMD may jointly accelerate tissue
damage.
Another noteworthy finding was the OR for the relationship between AMD and LOC387715/
ARMS2 increased with the addition of C5a into the model. Since the function of ARMS2 is
unknown, further research is needed. However, one possibility is that a tissue metalloproteinase
directly activates C5 leading to formation of C5a and C5b, with the former binding to its
receptor and the latter beginning the MAC.
Conclusion
Regardless of known genotype, both Bb and C5a are strongly associated with increased risk
of advanced AMD in this study. We found a new association between AMD and Bb and a new
significant inverse association with median level of CFH. Our case population consisted solely
of advanced AMD cases, most of which were documented progressors to GA and NV disease.
The GA and NV groups are in similar proportion and median levels are displayed for each
subtype. We expand on the relationships between AMD and complement components and
fragments by considering six genes (seven genetic loci) and covariates known to be related to
AMD, and we evaluated the effect of these genetic factors on function or levels of the
complement proteins. We also provide evidence of increased BMI in association with
complement activation fragments, suggesting that BMI itself increases the chronic activation
of the complement system. Our AMD prediction model with genetic, demographic, and
environmental factors was improved with the addition of plasma complement markers. Results
provide new evidence that the complement system, and particularly the alternative pathway,
is chronically activated in AMD. These findings contribute to our understanding of the
pathophysiology of advanced AMD.
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